Development of a syngeneic mouse model for events related to ovarian cancer.

By K. Roby, Christopher Taylor, Jeffrey P. Sweetwood, Ying Cheng, J. Pace, O. Tawfik, D. Persons, Peter G. Smith, P. Terranova. Carcinogenesis, 2000

603 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The mammalian ovary from genesis to revelation. (2009, background): “Repeated passaging of rodent OSE cultures results in spontaneous immortalization and malignant transformation based on loss of contact inhibition, substrate-independent growth, and tumor formation in nude mice (473,474,490).”
Treatment of disseminated ovarian cancer using nonviral interleukin‐12 gene therapy delivered intraperitoneally (2009, background): “This cell line has been modified by the stable transformation of vascular endothelial growth factor (VEGF)164 and enhanced green fluorescent protein (GFP) [28].”
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T Cell Rejection Function in Tumors (2013, neutral): “Terranova, University of Kansas, and used as described (44-46).”
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis (2015, result): “Similar survival results were observed in XBP1f/f CD11c-Cre mice developing parental orthotopic ovarian tumors (Roby et al., 2000) that do not ectopically expressDefb29 and Vegf-A (Figure 2J).”
Ovarian cancer: strategies for overcoming resistance to chemotherapy (2003, neutral): “Two of these models are based on the in vitro transformation of mouse ovarian surface epithelial cells — by either retroviral-mediated oncogene delivery or spontaneous transformation during passage — and their re-implantation into the peritoneal cavity of syngenic mic”